In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Gamida Cell (GMDA), with a price target of $13.00. The company’s shares closed last Thursday at $6.60.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 32.0% and a 65.1% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Inovio Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $16.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.70 and a one-year low of $2.60. Currently, Gamida Cell has an average volume of 252.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
